characterized by abnormal levels of liver enzymes, such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Currently, there are few therapies to slow down or alter the course of further disease progression in NASH. Therefore, there remains a need for effective NASH treatments.

SUMMARY OF THE DISCLOSURE

In one aspect, the present invention provides use of a therapeutically effective amount of a pharmaceutical composition comprising ethyl eicosapentanoate (EPA-E), eicosapentaenoic acid (EPA), or pharmaceutically acceptable amides, salts, ester or phospholipids of EPA in the manufacture of a medicament for treating a fatty liver disease or disorder in a subject in need thereof, wherein the subject is selected to have or suspected of having a fatty liver disease or disorder, wherein the subject is non diabetic, pre- diabetic, or mildly diabetic, and wherein the medicament is to be administered into the subject in need thereof and comprises a self-emulsifying composition comprising 50 to 95% by weight, a omega-3 polyunsaturated fatty acid or a pharmaceutically acceptable amide, salt, phospholipid or ester thereof.

[0004] The disclosure provides for a method for treating a fatty liver disease or disorder in a subject in need thereof, comprising selecting a subject having or suspected of having a fatty liver disease or disorder, wherein the subject is non diabetic, pre-diabetic, or mildly diabetic; or has normal or substantially normal biliary tract function; or has non or early stage hepatocyte apoptosis; and administering a therapeutically effective amount of a pharmaceutical composition comprising at least one compound selected from the group consisting of ethyl eicosapentanoate (EPA-E), eicosapentaenoic acid (EPA) and its pharmaceutically acceptable amides, salts, esters and phospholipids. In some cases EPA-E or EPA present may be at least 40% by weight in total of the fatty acids and their derivatives.

[0005] In some embodiments, the present disclosure provides for a method for treating a fatty liver disease or disorder in a subject in need thereof, comprising selecting a subject having or suspected of having a fatty liver disease or disorder, wherein the subject is non diabetic, pre-diabetic, or mildly

diabetic and undergoing medical nutrition therapy and/or physical exercise; and administering a therapeutically effective amount of a pharmaceutical composition comprising at least one compound selected from the group consisting of ethyl eicosapentanoate (EPA-E), eicosapentaenoic acid (EPA) and its pharmaceutically acceptable amides, salts, esters and phospholipids. In some cases the EPA-E or EPA present may be at least 40% by weight in total of the fatty acids and their derivatives.

[0006] In some embodiments, the present disclosure provides for a method for treating a fatty liver disease or disorder in a subject in need thereof, comprising selecting a subject having or suspected of having a fatty liver disease or disorder, wherein the subject presents non or early stage hepatocyte

CLAIMS

1. Use of a therapeutically effective amount of a pharmaceutical composition comprising ethyl eicosapentanoate (EPA-E), eicosapentaenoic acid (EPA), or pharmaceutically acceptable amides, salts, ester or phospholipids thereof in the manufacture of a medicament for treating a fatty liver disease or disorder in a subject in need thereof, wherein the subject is selected to have or suspected of having a fatty liver disease or disorder, wherein the subject is non diabetic, pre- diabetic, or mildly diabetic, and wherein the medicament is to be administered into the subject in need thereof.
2. Use of a therapeutically effective amount of a pharmaceutical composition comprising ethyl eicosapentanoate (EPA-E), eicosapentaenoic acid (EPA), or pharmaceutically acceptable amides, salts, ester or phospholipids thereof in the manufacture of medicament for treating a fatty liver disease or disorder in a subject in need thereof, wherein the subject is selected to have having or suspected of having a fatty liver disease or disorder, wherein
   i.the subject's serum HbA1c level is equal to or less than 6.4% or
   ii.the subject's fasting serum glucose level is equal to or less than 125 mg/dl; and
   wherein the medicament is to be administered to the subject in need thereof.
3. Use of a therapeutically effective amount of a pharmaceutical composition comprising ethyl eicosapentanoate (EPA-E), eicosapentaenoic acid (EPA), or pharmaceutically acceptable amides, salts, ester or phospholipids thereof in the manufacture of a medicament for treating a fatty liver disease or disorder in a subject in need thereof,
   wherein the subject is selected to have or suspected of having a fatty liver disease or disorder, wherein
   i. the subject's serum HbA1c level is equal to or less than 6.4% or
   ii. the subject's fasting serum glucose level is equal to or less than 125 mg/dl; and
   wherein the medicament is to be administered to the subject in need thereof and administration of the medicament results in an improvement of serum EPA/AA ratio as compared to a baseline EPA/AA ratio equal to or greater than 0.4 in the subject.
4. Use of a therapeutically effective amount of a pharmaceutical composition comprising ethyl eicosapentanoate (EPA-E), eicosapentaenoic acid (EPA), or pharmaceutically acceptable amides, salts, ester or phospholipids thereof in the manufacture of a medicament for treating a fatty liver disease or disorder in a subject in need thereof,
   wherein the subject is selected to have or suspected of having a fatty liver disease or disorder, wherein:
   i. the subject's serum HbA1c level is equal to or less than 6.4% or

ii. the subject's fasting serum glucose level is equal to or less than 125 mg/dl;

iii. wherein the subject is not treated with an anti-diabetic agent or has been previously treated with an anti-diabetic agent; and

wherein the medicament is to be administered to the subject in need thereof.

5. Use of a therapeutically effective amount of a pharmaceutical composition comprising ethyl eicosapentanoate (EPA-E), eicosapentaenoic acid (EPA), or pharmaceutically acceptable amides, salts, ester or phospholipids thereof in combination with one or more anti-diabetic agents in the manufacture of a medicament for treating a fatty liver disease or disorder in a subject in need thereof, wherein the subject is selected to have or suspected of having a fatty liver disease or disorder, wherein

i. the subject's serum HbA1c level is equal to or less than 6.4% or

ii. the subject's fasting serum glucose level is equal to or less than 125 mg/dl; and

wherein the medicament is to be administered to the subject in need thereof.

6. Use of a therapeutically effective amount of a pharmaceutical composition comprising ethyl eicosapentanoate (EPA-E), eicosapentaenoic acid (EPA), or pharmaceutically acceptable amides, salts, ester or phospholipids thereof in the manufacture of a medicament for treating a fatty liver disease or disorder in a subject in need thereof, wherein said subject is to be selected to have: :

i. NAS score greater than or equal to 3; or

ii. steatosis score equal to or greater than 1; or

iii. lobular inflammation score equal to or greater than 1; or

iv. ballooning score equal to or greater than 1; or

v. fibrosis score equal to or greater than 1;

and wherein the medicament is to be administered to the subject; and wherein the subject's serum HbA1c level is equal to or less than 6.4% or ii) the subject's fasting serum glucose level is equal to or less than 125 mg/dl.

7. Use of a therapeutically effective amount of a pharmaceutical composition comprising ethyl eicosapentanoate (EPA-E), eicosapentaenoic acid (EPA), or pharmaceutically acceptable amides, salts, ester or phospholipids thereof in the manufacture of a medicament for treating a fatty liver disease or disorder in a subject in need thereof, wherein said subject is selected to have or suspected of having a fatty liver disease or disorder, wherein the subject shows a normal or substantially normal biliary function or a serum gamma glutamyl transferase (GGT) level is normal or substantially normal, and wherein said medicament is to be administered to the subject.

8. Use of a therapeutically effective amount of a pharmaceutical composition comprising ethyl eicosapentanoate (EPA-E), eicosapentaenoic acid (EPA), or pharmaceutically acceptable

amides, salts, ester or phospholipids thereof in the manufacture of a medicament for treating a fatty liver disease or disorder in a subject in need thereof, wherein the subject is selected to have or suspected of having a fatty liver disease or disorder, wherein the subject shows a normal or substantially normal biliary function or a serum gamma glutamyl transferase (GGT) level equal to or less than 33 IU/L or GGT level equal to or less than 30 IU/L for men and GGT level equal to or less than 24 IU/L for women, and wherein said medicament is to be administered to the subject.

9. Use of an effective amount of a pharmaceutical composition comprising ethyl eicosapentanoate (EPA-E), eicosapentaenoic acid (EPA), or pharmaceutically acceptable amides, salts, ester or phospholipids thereof in the manufacture of a medicament for treating a fatty liver disease or disorder in a subject in need thereof, wherein said subject is selected to have or suspected of having a fatty liver disease or disorder, wherein the subject shows a normal or substantially normal biliary function or a serum gamma glutamyl transferase (GGT) level equal to or less than 33 IU/L,
wherein said medicament is to be administered to the subject and the subject has: ;
(a) improving the steatosis and lobular inflammation condition of said subject, and no worsening of said fibrosis stage score; and
(b) the subject exhibits the following changes in said at least one marker as compared to a baseline pretreatment level of at least 1% reduction for ALT, AST, TG, TG/HDL ratio, Free fatty acid, AA, MUFA, Palmitoleic acid, Oleic acid, Oleic acid/Stearic acid ratio, Palmitoleic acid/Palmitic acid ratio, Stearic acid/Palmitic acid ratio, y-linoleic acid/Linoleic acid ratio, Adrenic acid/AA ratio, Ferritin, Thioredoxin, TNF α, sTNF-R1, sTNF-R2, Hs-CRP, CTGF, sCD40, Leptin, complement factor D, CK18 fragment, serum HMGB1, Fas, Hyaluronic acid, Type IV collagen (7s domain), procollagen III peptide or PAI-1; at least 5% increase for EPA or EPA/AA ratio; at least 1% increase for DPA, AA/Homo-γ-linoleic acid ratio or Serum adiponectin; no worsening of ALP, bilirubin, GGT, Albumin, HDL-C, LDL-C, TC, non-HDL-C, HOMA-IR, HbA1c, Glucose, Fasting plasma glucose, postprandial plasma glucose, OGTT, platelet count or BMI.

10. Use of a therapeutically effective amount of a pharmaceutical composition comprising ethyl eicosapentanoate (EPA-E), eicosapentaenoic acid (EPA), or pharmaceutically acceptable amides, salts, ester or phospholipids thereof in the manufacture of a medicament for treating a fatty liver disease or disorder in a subject in need thereof, wherein said subject is selected with at least one criteria selected from the group consisting of NAS score, steatosis score, lobular inflammation score, ballooning score and fibrosis stage is indicative of fatty liver disease; and wherein the subject shows a serum gamma glutamyl transferase (GGT) level equal to or less than 33 IU/L; and

wherein said medicament is to be administered to the subject in need thereof .

11. Use of a therapeutically effective amount of a pharmaceutical composition comprising ethyl eicosapentanoate (EPA-E), eicosapentaenoic acid (EPA), or pharmaceutically acceptable amides, salts, ester or phospholipids thereof to the subject in the manufacture of a medicament for treating a fatty liver disease or disorder in a subject in need thereof, wherein the subject is selected to have:
    i. NAS score greater than or equal to 3; or
    ii. steatosis score equal to or greater than 1; or
    iii. lobular inflammation score equal to or greater than 1; or
    iv. ballooning score equal to or greater than 1; or
    v. fibrosis score equal to or greater than 1;

    wherein the subject's gamma glutamyl transferase (GGT) serum level is determined; and wherein the medicament is to be administered to the subject in need thereof if the i) shows a serum gamma glutamyl transferase (GGT) level equal to or less than 33 IU/L.
12. Use of a therapeutically effective amount of a pharmaceutical composition comprising ethyl eicosapentanoate (EPA-E), eicosapentaenoic acid (EPA), or pharmaceutically acceptable amides, salts, ester or phospholipids thereof in the manufacture of a medicament for treating a fatty liver disease or disorder in a subject in need thereof, wherein the subject is selected to have or suspected of having a fatty liver disease or disorder, wherein the subject shows non or early stage hepatocyte apoptosis and wherein the medicament is to be administered to the subject.
13. Use of a therapeutically effective amount of a pharmaceutical composition comprising ethyl ethyl eicosapentanoate (EPA-E), eicosapentaenoic acid (EPA), or pharmaceutically acceptable amides, salts, ester or phospholipids thereof in the manufacture of a medicament for treating a fatty liver disease or disorder in a subject in need thereof, wherein said subject is selected to have or suspected of having a fatty liver disease or disorder, wherein the subject shows non or early stage hepatocyte apoptosis or a serum soluble Fas (sFas) level equal to or less than 10.0 ng/mL and/or a serum cytokeratin-18 M30 (M30) level equal to or less than 1500 U/L or a NASH risk score equal to or less than 3.0, and wherein said medicament is to be administered to the subject in need thereof .
14. Use of an effective amount of a pharmaceutical composition comprising ethyl eicosapentanoate (EPA-E), eicosapentaenoic acid (EPA), or pharmaceutically acceptable amides, salts, ester or phospholipids thereof in the manufacture of a medicament for treating a fatty liver disease or disorder in a subject in need thereof, wherein said subject is to be selected to have or suspected of having a fatty liver disease or disorder, wherein the subject shows non or early stage hepatocyte apoptosis or a serum soluble Fas (sFas) level equal to or

less than 10.0 ng/mL and/or a serum cytokeratin-18 M30 (M30) level equal to or less than 1500 U/L or a NASH risk score equal to or less than 3.0,

wherein said medicament is to be administered to the subject and the medicament ;

(a) improved the steatosis and lobular inflammation condition of said subject, and no worsening of said fibrosis stage score; and

(b) the subject exhibits the following changes in said at least one marker as compared to a baseline pretreatment level of at least 1% reduction for ALT, AST, TG, TG/HDL ratio, Free fatty acid, AA, MUFA, Palmitoleic acid, Oleic acid, Oleic acid/Stearic acid ratio, Palmitoleic acid/Palmitic acid ratio, Stearic acid/Palmitic acid ratio, γ-linoleic acid/Linoleic acid ratio, Adrenic acid/AA ratio, Ferritin, Thioredoxin, TNF α, sTNF-R1, sTNF-R2, Hs-CRP, CTGF, sCD40, Leptin, complement factor D, CK18 fragment, serum HMGB1, Fas, Hyaluronic acid, Type IV collagen (7s domain), procollagen III peptide or PAI-1; at least 5% increase for EPA or EPA/AA ratio; at least 1% increase for DPA, AA/Homo-γ-linoleic acid ratio or Serum adiponectin; no worsening of ALP, bilirubin, GGT, Albumin, HDL-C, LDL-C, TC, non-HDL-C, HOMA-IR, HbA1c, Glucose, Fasting plasma glucose, postprandial plasma glucose, OGTT, platelet count, M30, sFas, NASH risk score or BMI.

15. Use of a therapeutically effective amount of a pharmaceutical composition comprising ethyl eicosapentanoate (EPA-E), eicosapentaenoic acid (EPA), or pharmaceutically acceptable amides, salts, ester or phospholipids thereof in the manufacture of a medicament for treating a fatty liver disease or disorder in a subject in need thereof, wherein said subject is selected with at least one criteria selected from the group consisting of NAS score, steatosis score, lobular inflammation score, ballooning score and fibrosis stage is indicative of fatty liver disease; and wherein the subject shows non or early stage hepatocyte apoptosis or a serum soluble Fas (sFas) level equal to or less than 10.0 ng/mL and/or a serum cytokeratin-18 M30 (M30) level equal to or less than 1500 U/L or a NASH risk score equal to or less than 3.0; and

wherein said medicament is to be administered to the subject in need thereof.

16. Use of a therapeutically effective amount of a pharmaceutical composition comprising ethyl ethyl eicosapentanoate (EPA-E), eicosapentaenoic acid (EPA), or pharmaceutically acceptable amides, salts, ester or phospholipids thereof to the subject in the manufacture of a medicament for treating a fatty liver disease or disorder in a subject in need thereof, wherein said subject is selected to have:

i. NAS score greater than or equal to 3; or
ii. steatosis score equal to or greater than 1; or
iii. lobular inflammation score equal to or greater than 1; or
iv. ballooning score equal to or greater than 1; or

v. fibrosis score equal to or greater than 1;

wherein the subject's soluble Fas (sFas) serum level and/or serum cytokeratin-18 M30 (M30) level or NASH risk score is determined; and

(a) wherein the medicament is to be administered to the subject if the i) shows a sFas level equal to or less than 10.0 ng/mL and/or M30 level equal to or less than 1500 U/L or a NASH risk score equal to or less than 3.0.

17. The use of any of claims 5, wherein the anti-diabetic agent is selected from the following group: PPARγ agonists, biguanides, protein tyrosine phosphatase-1B (PTP-1B) inhibitors, meglitinides, α glucoside hydrolase inhibitors, insulin secreatagogues, A2 antagonists, insulin and related compounds, PPAR dual agonists, SGLT2 inhibitors, GSK 3β/GSK 3 inhibitors, dipeptidyl peptidase IV (DP-IV) inhibitors, peptides, sulfonylureas, and nonsulfonylurea secretagogues.
18. The use of any of claims 1-16, wherein the fatty liver disease or disorder is selected from the group consisting of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatits (NASH).
19. The use of any of claims 1-16, wherein selection of a subject having or suspected of having a fatty liver disease or disorder comprises selecting a subject having a score selected from the group consisting of: a NAS score greater than or equal to 3, a steatosis score equal to or greater than 1, a lobular inflammation score equal to or greater than 1, a ballooning score equal to or greater than 1 and a fibrosis score equal to or greater than 1.
20. The use of any of claims 1-16, wherein fatty liver disease is characterized by the baseline pretreatment level in the subject of at least one criteria selected from the group consisting of ALT in a range of 10 to 300 IU/L, AST in a range of 10 to 250 IU/L, HDL/C in a range of 25 to 55 mg/dl, LDL-C in a range of 100 to 200 mg/dl, triglycerides in a range of 100 to 1000 mg/dl, TC in a range of 170 to 300 mg/dl, High TG and low HDL-C, TG/HDL-C ratio in a range of 3.75 to 10, non-HDL-C in a range of 100 to 250 mg/dl, Free fatty acid in a range of 400 to 1000 μ Eq/L, HOMA-IR in a range of 1.5 to 5, HbA1c in a range of 5.7 to 10%, Fasting plasma glucose in a range of 100 to 200 mg/dl, impaired glucose tolerance and metabolic syndrome.
21. The use of any of claims 1-16, wherein a therapeutically effective amount of EPA-E to be administered to the subject is an amount between about 1800 and about 2700 mg per day.
22. The use of any of claims 1-16, wherein a therapeutically effective amount of EPA-E to be administered to the subject is at least 1800 mg per day.
23. The use of any of claims 1-16, wherein a therapeutically effective amount of EPA-E to be administered to the subject is at least 2700 mg per day.

24. The use of any of claims 1-16, wherein said reduced ALT value is at least 5% lower than said baseline ALT value and/or said reduced AST value is at least 5% lower than said baseline AST value.
25. The use of any of claims 1-16, wherein after administration of ethyl eicosapentanoate for at least 3 months, said subject exhibits the following changes in said at least one marker as compared to the baseline level of at least 1% reduction for ALT, AST, TG, TG/HDL ratio, Free fatty acid, AA, MUFA, Palmitoleic acid, Oleic acid, Oleic acid/Stearic acid ratio, Palmitoleic acid/Palmitic acid ratio, Adrenic acid/AA ratio, Ferritin, Thioredoxin, TNF α, sTNF-R1, sTNF-R2, Hs-CRP, CRGF, sCD40, Leptin, complement factor D, CK18 fragment, serum HMGB1, Fas, Hyaluronic acid, Type IV collagen (7s domain), procollagen III peptide or PAI-1; at least 5% increase for EPA or EPA/AA ratio; at least 1% increase for DPA, AA/Homo-γ-linoleic acid ratio or Serum adiponectin; no worsening of ALP, bilirubin, GGT, Albumin, HDL-C, LDL-C, TC, non-HDL-C, HOMA-IR, HbA1c, Glucose, Fasting plasma glucose, postprandial plasma glucose, OGTT, platelet count or BMI.
26. The use of claims 1, 2, 4, 5, 6, or13-16, further comprising an improvement in serum EPA/AA ratio as compared to a baseline EPA/AA ratio.
27. The use of claim26, wherein the improvement in serum EPA/AA ratio as compared to a baseline EPA/AA ratio is equal to or greater than 0.4.
28. The use of any of claims 1-16, wherein the medicament comprises a self-emulsifying composition comprising 50 to 95% by weight, a omega-3 polyunsaturated fatty acid or a pharmaceutically acceptable amide, salt, phospholipid or ester thereof.
29. The use of any of claims 1-16, wherein the medicament comprises a self-emulsifying composition comprising 50 to 95% by weight, of EPA-E, EPA or pharmaceutically acceptable amides, salts, esters or phospholipids thereof.
30. The use of any of claims 1-16, wherein the medicament comprises 5 to 50% by weight of an emulsifier having a hydrophilic lipophilic balance of at least 10.
31. The use of any of claims30, wherein the medicament comprises ethanol content up to 4% by weight in relation to the total content of the compound and the emulsifier.
32. The use of any of claims30, wherein the emulsifier is at least one member selected from the group consisting of polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene castor oil, polyethylene glycol fatty acid ester, polyoxyethylene polyoxypropylene glycol, sucrose fatty acid ester, sorbitan fatty acid ester, glycerin fatty acid ester and lecithin.
33. The use of any of claims30, wherein the medicament contains a lecithin.
34. The use of any of claims 30, wherein the medicament contains a polyhydric alcohol.

35. The use of any of claims 16, wherein the medicament contains at least one member selected from the group consisting of eicosapentaenoic acid, docosahexaenoic acid, and their pharmaceutically acceptable amides, salts, esters and phospholipids.
36. The use of any of claims 1-16, wherein EPA-E, EPA or pharmaceutically acceptable amides, salts, esters or phospholipids thereof present in the medicament is at least 40% by weight in total of the fatty acids and derivatives.
37. The use of any of claims 1-160, wherein the medicament is Epadel™, Lovaza™, Omacor ™, Lotriga™ or Vascepa ™.

CLAIMS

1. Use of a therapeutically effective amount of a pharmaceutical composition comprising ethyl eicosapentanoate (EPA-E), eicosapentaenoic acid (EPA), or pharmaceutically acceptable amides, salts, ester or phospholipids of EPA in the manufacture of a medicament for treating a fatty liver disease or disorder in a subject in need thereof, wherein the subject is selected to have or suspected of having a fatty liver disease or disorder, wherein the subject is non diabetic, pre- diabetic, or mildly diabetic, and wherein the medicament is to be administered into the subject in need thereof and comprises a self-emulsifying composition comprising 50 to 95% by weight, a omega-3 polyunsaturated fatty acid or a pharmaceutically acceptable amide, salt, phospholipid or ester thereof.
2. The use of claim 1, wherein the fatty liver disease or disorder is selected from the group consisting of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatits (NASH).
3. The use of claim 1, wherein selection of a subject having or suspected of having a fatty liver disease or disorder comprises selecting a subject having a score selected from the group consisting of: a NAS score greater than or equal to 3, a steatosis score equal to or greater than 1, a lobular inflammation score equal to or greater than 1, a ballooning score equal to or greater than 1 and a fibrosis score equal to or greater than 1.
4. The use of claim 1, wherein fatty liver disease is characterized by the baseline pretreatment level in the subject of at least one criteria selected from the group consisting of ALT in a range of 10 to 300 IU/L, AST in a range of 10 to 250 IU/L, HDL/C in a range of 25 to 55 mg/dl, LDL-C in a range of 100 to 200 mg/dl, triglycerides in a range of 100 to 1000 mg/dl, TC in a range of 170 to 300 mg/dl, High TG and low HDL-C, TG/HDL-C ratio in a range of 3.75 to 10, non-HDL-C in a range of 100 to 250 mg/dl, Free fatty acid in a range of 400 to 1000 μ Eq/L, HOMA-IR in a range of 1.5 to 5, HbA1c in a range of 5.7 to 10%, Fasting plasma glucose in a range of 100 to 200 mg/dl, impaired glucose tolerance and metabolic syndrome.
5. The use of claim 1, wherein a therapeutically effective amount of EPA-E to be administered to the subject is an amount between about 1800 and about 2700 mg per day.
6. The use of claim 1, wherein a therapeutically effective amount of EPA-E to be administered to the subject is at least 1800 mg per day.
7. The use of claim 1, wherein a therapeutically effective amount of EPA-E to be administered to the subject is at least 2700 mg per day.

8. The use of claim 4, wherein ALT value is reduced at least 5% lower than said baseline ALT value and/or AST value is reduced at least 5% lower than said baseline AST value.
9. The use of claim 1, wherein after administration of ethyl eicosapentanoate for at least 3 months, said subject exhibits the following changes in at least one marker as compared to the baseline level of at least 1% reduction for ALT, AST, TG, TG/HDL ratio, Free fatty acid, AA, MUFA, Palmitoleic acid, Oleic acid, Oleic acid/Stearic acid ratio, Palmitoleic acid/Palmitic acid ratio, Adrenic acid/AA ratio, Ferritin, Thioredoxin, TNF α, sTNF-R1, sTNF-R2, Hs-CRP, CRGF, sCD40, Leptin, complement factor D, CK18 fragment, serum HMGB1, Fas, Hyaluronic acid, Type IV collagen (7s domain), procollagen III peptide or PAI-1; at least 5% increase for EPA or EPA/AA ratio; at least 1% increase for DPA, AA/Homo-γ-linoleic acid ratio or Serum adiponectin; no worsening of ALP, bilirubin, GGT, Albumin, HDL-C, LDL-C, TC, non-HDL-C, HOMA-IR, HbA1c, Glucose, Fasting plasma glucose, postprandial plasma glucose, OGTT, platelet count or BMI.
10. The use of claim 1, further comprising an improvement in serum EPA/AA ratio as compared to a baseline EPA/AA ratio.
11. The use of claim 10, wherein the improvement in serum EPA/AA ratio as compared to a baseline EPA/AA ratio is equal to or greater than 0.4.
12. The use of claim 1, wherein the medicament comprises a self-emulsifying composition comprising 50 to 95% by weight, of EPA-E, EPA or pharmaceutically acceptable amides, salts, esters or phospholipids of EPA.
13. The use of claim 1, wherein the medicament comprises 5 to 50% by weight of an emulsifier having a hydrophilic lipophilic balance of at least 10.
14. The use of claim 13, wherein the medicament comprises ethanol content up to 4% by weight in relation to the total content of the compound and the emulsifier.
15. The use of claim 13, wherein the emulsifier is at least one member selected from the group consisting of polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene castor oil, polyethylene glycol fatty acid ester, polyoxyethylene polyoxypropylene glycol, sucrose fatty acid ester, sorbitan fatty acid ester, glycerin fatty acid ester and lecithin.
16. The use of claim 13, wherein the medicament contains a lecithin.
17. The use of claim 13, wherein the medicament contains a polyhydric alcohol.
18. The use of claim 1, wherein the medicament contains at least one member selected from the group consisting of eicosapentaenoic acid, docosahexaenoic acid, and their pharmaceutically acceptable amides, salts, esters and phospholipids.

19. The use of claim 1, wherein EPA-E, EPA or pharmaceutically acceptable amides, salts, esters or phospholipids of EPA present in the medicament is at least 40% by weight in total of the fatty acids and derivatives.